Omnicell Inc

Análisis de la acción Omnicell Inc (OMCL)

$33.080

-0.327 (-0.99%)Al cierre

Loading chart…
High
33.760
Open
33.520
VWAP
33.23
Vol
538.72K
Mkt Cap
1.21B
Low
32.865
Amount
17.90M
EV/EBITDA, TTM
9.00

Omnicell, Inc. is a healthcare technology provider focused on autonomous medication management, by unifying automation and AI-enabled intelligence, optimized by expert services, to drive clinical and business outcomes that are helping to improve efficiency and enhance patient safety for healthcare facilities. The Company is focused on helping its customers define and deliver a medication management strategy designed for pharmacists and nurses to focus on patient care rather than administrative tasks, and to drive improved clinical, operational, and financial outcomes across all care settings. It provides a range of points of care medication and supplies dispensing systems, including automated systems and offers advanced automation solutions, including robotics designed to automate work, streamline workflows, and reduce human error. It provides central pharmacy automation solutions for both medication dispensing and IV compounding and provides patient engagement solutions.

AI analysis of Omnicell Inc (OMCL)

sell

Omnicell Inc is not a good buy right now. The current price is $33.08, which is significantly lower than the analyst price targets ranging from $45 to $65, indicating potential upside. However, the RSI is at a very low 19.425, suggesting the stock is oversold, but the recent negative sentiment from insiders selling shares has increased by 151.38%. This raises concerns about the stock's short-term performance.

Analyst Ratings (8)

+63.85% upside
Buy
5 Buy
3 Hold
0 Sell
Current: 33.08
Mínimo
46.00
Promedio
54.20
Máximo
63.00

Piper Sandler

2026-08-03

Precio objetivo

$45

Overweight

KeyBanc

2026-07-31

Precio objetivo

$65

Overweight

Wells Fargo

2026-07-31

Precio objetivo

$50

Overweight

Craig-Hallum

2026-04-29

Precio objetivo

$55

Buy

KeyBanc

2026-04-29

Precio objetivo

$70

Overweight

Métricas de valoración

The current forward P/E ratio for Omnicell Inc (OMCL) is 29.50, compared to its 5-year average forward P/E of 30.70.

Forward P/E

Fair
5Y Average P/E
30.70
Current P/E
29.50
Sobrevalorada
42.24
Infravalorada
19.16

Forward EV/EBITDA

Undervalued
5Y Average EV/EBITDA
18.23
Current EV/EBITDA
9.00
Sobrevalorada
25.81
Infravalorada
10.65

Forward P/S

Fair
5Y Average P/S
2.28
Current P/S
1.18
Sobrevalorada
3.66
Infravalorada
0.91

Alphio AI Price Scenarios for OMCL

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%OMCL

$32.55

Precio del escenario

B

Base

Base · 50%OMCL

$27.79

Precio del escenario

B

Bear

Bear · 25%OMCL

$24.88

Precio del escenario

Whales holding OMCL

C

Cramer Rosenthal McGlynn LLC

+ HoldingOMCL

-0.09%

3M Return

Cronología de eventos

2026-07-30 (ET)

07:30:00

Sees 2026 Revenue at $1.23B-$1.25B

07:30:00

Sees Q3 Revenue of $301M-$307M

2026-07-01 (ET)

08:30:00

Omnicell Appoints Nnamdi Njoku as President

2026-04-29 (ET)

08:10:00

Omnicell Appoints Rick Couldry as Chief Pharmacy and Clinical Officer

Noticias

OMCL FAQ — answered by Alphio AI

Omnicell, Inc. is a healthcare technology provider focused on autonomous medication management, by unifying automation and AI-enabled intelligence, optimized by expert services, to drive clinical and business outcomes that are helping to improve efficiency and enhance patient safety for healthcare facilities. The Company is focused on helping its customers define and deliver a medication management strategy designed for pharmacists and nurses to focus on patient care rather than administrative tasks, and to drive improved clinical, operational, and financial outcomes across all care settings. It provides a range of points of care medication and supplies dispensing systems, including automated systems and offers advanced automation solutions, including robotics designed to automate work, streamline workflows, and reduce human error. It provides central pharmacy automation solutions for both medication dispensing and IV compounding and provides patient engagement solutions. It operates in the Healthcare sector (ELECTRONIC COMPUTERS industry).

Omnicell Inc is not a good buy right now. The current price is $33.08, which is significantly lower than the analyst price targets ranging from $45 to $65, indicating potential upside. However, the RSI is at a very low 19.425, suggesting the stock is oversold, but the recent negative sentiment from insiders selling shares has increased by 151.38%. This raises concerns about the stock's short-term performance.

8 analysts cover OMCL: 5 rate it Buy, 3 Hold and 0 Sell. The average price target is 54.20.

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empieza gratis